AU2013334599B2 - Combination - Google Patents

Combination Download PDF

Info

Publication number
AU2013334599B2
AU2013334599B2 AU2013334599A AU2013334599A AU2013334599B2 AU 2013334599 B2 AU2013334599 B2 AU 2013334599B2 AU 2013334599 A AU2013334599 A AU 2013334599A AU 2013334599 A AU2013334599 A AU 2013334599A AU 2013334599 B2 AU2013334599 B2 AU 2013334599B2
Authority
AU
Australia
Prior art keywords
cancer
compound
cetuximab
leukemia
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013334599A
Other languages
English (en)
Other versions
AU2013334599A1 (en
Inventor
Joel GRESHOCK
Axel Hoos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013334599A1 publication Critical patent/AU2013334599A1/en
Application granted granted Critical
Publication of AU2013334599B2 publication Critical patent/AU2013334599B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013334599A 2012-10-25 2013-10-24 Combination Ceased AU2013334599B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718430P 2012-10-25 2012-10-25
US61/718,430 2012-10-25
PCT/US2013/066564 WO2014066606A2 (en) 2012-10-25 2013-10-24 Combination

Publications (2)

Publication Number Publication Date
AU2013334599A1 AU2013334599A1 (en) 2015-04-30
AU2013334599B2 true AU2013334599B2 (en) 2016-03-10

Family

ID=50545472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334599A Ceased AU2013334599B2 (en) 2012-10-25 2013-10-24 Combination

Country Status (11)

Country Link
US (1) US20150273057A1 (enExample)
EP (1) EP2911673A4 (enExample)
JP (1) JP2016503399A (enExample)
KR (1) KR20150070393A (enExample)
CN (1) CN104812391A (enExample)
AU (1) AU2013334599B2 (enExample)
BR (1) BR112015009134A2 (enExample)
CA (1) CA2889530A1 (enExample)
MX (1) MX2015005307A (enExample)
RU (1) RU2015119218A (enExample)
WO (1) WO2014066606A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181243B2 (en) * 2013-12-03 2015-11-10 Hangzhou Pushai Pharmaceutical Technology Co. Ltd. Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof
MX2016007653A (es) * 2013-12-12 2016-10-13 Novartis Ag Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
KR20170068409A (ko) * 2014-09-16 2017-06-19 이즈 참 리미티드 항-egfr 항체 및 그의 용도
US20170027951A1 (en) * 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
US20190125864A1 (en) * 2016-04-15 2019-05-02 Eli Lilly And Company Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma
BR112018074941A2 (pt) * 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
KR20230154793A (ko) * 2020-12-11 2023-11-09 에라스카, 아이엔씨. 암 치료를 위한 병용 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2298768E (pt) * 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008101840A1 (en) * 2007-02-23 2008-08-28 F. Hoffmann-La Roche Ag Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells
EP2249644A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
MY165154A (en) * 2009-08-24 2018-02-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
DK4397376T3 (da) * 2009-10-16 2026-02-23 Novartis Ag Kombination der omfatter en mek-hæmmer og en b-raf-hæmmer
US10016440B2 (en) * 2010-04-21 2018-07-10 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
RU2568258C2 (ru) * 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
PT2897620T (pt) * 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Meira, DD et al (2009) Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. British Journal of Cancer 101: 782-791. *

Also Published As

Publication number Publication date
RU2015119218A (ru) 2016-12-20
BR112015009134A2 (pt) 2017-07-04
EP2911673A2 (en) 2015-09-02
WO2014066606A3 (en) 2014-07-10
EP2911673A4 (en) 2016-05-18
WO2014066606A8 (en) 2015-06-04
US20150273057A1 (en) 2015-10-01
JP2016503399A (ja) 2016-02-04
WO2014066606A2 (en) 2014-05-01
MX2015005307A (es) 2015-07-17
CA2889530A1 (en) 2014-05-01
KR20150070393A (ko) 2015-06-24
CN104812391A (zh) 2015-07-29
AU2013334599A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
AU2010306653B2 (en) Combination
US20160367662A1 (en) Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
US20150273057A1 (en) Combination
AU2014321456B2 (en) Combination drug therapy
HK40106558B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40081897A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40081897B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
WO2015042027A1 (en) Combination drug therapy
HK1167287A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK1167287B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40011584A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40011584B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
WO2014158467A1 (en) Combination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired